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INTRODUCTION
Flt3 ligand (FL) is a transmembrane protein that binds
to the flt3 receptor, which is restricted to bone marrow
(BM) cells and thymic progenitor cells [1,2]. Deletion of ﬂt3
leads to multipotential stem cell deﬁciency [3]. In vivo, FL
stimulates the proliferation of highly enriched human and
murine hematopoietic stem cells [4-10]. FL-mobilized
peripheral blood stem cells (PBSCs) have been shown to
rescue mice from irradiation-induced aplasia and to permit
long-term multilineage hematopoiesis [11]. Thus, FL treat-
ment may be effective for mobilizing autologous PBSCs,
which have been used to reconstitute allograft recipients
[12-15]. In some reports [12] but not others [14,15], granu-
locyte colony–stimulating factor (G-CSF)-mobilized PBSCs
appear to have a reduced capacity to induce acute graft-ver-
sus-host disease (GVHD) compared with BM grafts.
Because FL has potent PBSC-mobilizing effects, FL could
be used as a mobilizing agent for allogeneic PBSCs if such
mobilization does not impair the alloengraftment capacity of
PBSCs and if the GVHD risk is not increased by donor FL
treatment. In a mouse model, investigators have shown that
FL-mobilized PBSCs were more effective than nonmobi-
lized PBSCs in reconstituting lethally irradiated major his-
tocompatibility complex (MHC)-disparate recipients [16].
However, those experiments were designed primarily to test
the rescue capacity of FL-mobilized PBSCs rather than
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ABSTRACT
Flt3 ligand (FL) is a hematopoietic cytokine that has been shown to facilitate the expansion of dendritic cells (DCs)
and the generation of antitumor immune responses. In addition, the use of FL in mobilizing peripheral blood pro-
genitor cells is being investigated. In the present study, we sought to quantify the influence of FL-treated donor
cells on graft-versus-host disease (GVHD). FL treatment resulted in a marked expansion in the absolute number
of myeloid- and lymphoid-related DCs and a reduction in the proportion of donor splenic T cells. Irradiated recip-
ients who were given splenocytes from FL-treated donors had reduced GVHD lethality compared with controls
due to the infusion of fewer mature T cells. Highly purified T cells from FL-treated donors produced comparable
in vitro alloresponses and there was no evidence of a skewing toward T-helper type 1 (interleukin [IL]-2, inter-
feron-γ) or T-helper type 2 (IL-4, IL-10) cytokine production. The GVHD lethality associated with purified T
cells obtained from FL-treated or control donors was comparable. In contrast, FL treatment of recipients resulted
in a significant increase in GVHD lethality. Increased lethality was observed even when the infusions of allogeneic
T cells and FL were delayed until 3 weeks post–bone marrow transplantation (BMT). Our data indicate that FL
treatment of donors does not increase GVHD risk, but treatment of recipients increases GVH lethality even if FL
treatment is delayed until later post-BMT.
KEY WORDS:
Flt3 ligand • Graft-versus-host disease • GVHD lethality
Biology of Blood and Marrow Transplantation 7:197-207 (2001)
© 2001 American Society for Blood and Marrow Transplantation ASBMT
Supported in part by the Children’s Cancer Research Fund and National Insti-
tutes of Health grants R01 CA72669, R01 AI 34495, and R01 HL-63452
B.R. Blazar et al.
198
their GVH potential. The risk of GVHD induction using
T cells from FL-treated donors has not been assessed in the
setting of full hematopoietic rescue.
In addition to its hematopoietic effects, FL has a pro-
found effect on the generation of functionally mature den-
dritic cells (DCs) in multiple organs in mice [17]. DCs are
potent antigen-presenting cells (APCs) that stimulate naive-
and memory T-cell immune responses and have been used
successfully to treat mice with solid tumors and to generate
immune responses in humans [18-27]. FL has also been
shown to stimulate the generation and function of murine
and human natural killer (NK) effector cells [28-33]. Because
FL administration to recipients post–bone marrow trans-
plantation (BMT) could be useful in speeding lymphohe-
matopoiesis and in providing antitumor effects post-BMT,
we sought to determine whether FL administration to recipi-
ents post-BMT would affect the development of GVHD.
In the present study, we addressed 2 important issues
regarding the use of FL in the context of BMT. First, we
assessed the GVHD-inducing capacity of allogeneic cells
obtained from FL-treated donors. FL treatment of donors
markedly increased the number of splenocytes consistent
with peripheral cell expansion without affecting GVHD-
inducing capacity of the donor T cells. Second, we explored
the use of FL for treatment of allogeneic BMT recipients.
FL treatment of recipients beginning either on the day of
BMT or later, along with delayed lymphocyte infusion
(DLI). In both instances, FL treatment led to increased
GVHD-related mortality. These data have important clini-
cal ramiﬁcations.
MATERIALS AND METHODS
Mice
B10.BR/SgSnJ (B10.BR) (H-2k) mice were purchased
from the Jackson Laboratory (Bar Harbor, ME) and
C57BL/6 (H-2b) (B6) mice were purchased from the
National Institutes Health (NIH) (Bethesda, MD). B10.BR-
CD45.1 (H2k/k; CD45.1) mice were generated by crossing
and intercrossing B6-CD45.1 (NIH) and B10.BR (CD45.2)
recipients. Mice were housed in microisolator cages in a
specific pathogen-free facility and cared for according to
institutional Research Animal Resources guidelines. Donors
and recipients were 8 to 12 weeks of age.
Flt3 Ligand Protein Administration
Recombinant human FL protein was produced in
human Chinese hamster ovary cells at Immunex (Seattle,
WA). For donor treatment, mice were injected subcuta-
neously with 10 µg of FL for 10 days, which represents the
time period when the highest number of splenic DCs are
generated in vivo [34]. For recipient treatment post-BMT,
mice were given either saline or FL for 21 days (days 0-20),
a dosage known to generate potent antitumor responses in
naive mice [35,36]. For DLI studies, donor splenocytes (25
or 50 × 106) were given on day 21 post-BMT. Because FL at
a dose of 10 µg/day results in peak DC expansion on day 10
after initiating injections in naive mice, FL was given for 21
days beginning on day 11 post-BMT so that the DLI would
be administered at the time of peak DC expansion, or
beginning on day 18 so that future experiments could be
timed to provide optimal DC expansion at the time of
tumor challenge, 7 days post-DLI [37-39].
Bone Marrow Transplantation
B10.BR and B6 recipients were conditioned with 8.0 Gy
of total body irradiation (Philips RT 250 Orthovoltage
Therapy Unit; Philips Medical Systems, Brookfield, WI).
Donor BM was depleted of T cells with anti-Thy1.2 (30-H-
12) plus rabbit complement [39]. Eight million BM cells
were infused. To induce GVHD, supplemental T cells con-
sisting of either splenocytes or purified lymph node (LN)
T cells were infused along with BM cells. Splenocytes were
given at doses of 15 × 106 cells per mouse. For DLI experi-
ments, irradiated recipients were reconstituted with 20 × 106
T cell–depleted BM cells. On day 21 post-BMT, donor
splenocytes were infused at a dose of 25 or 50 × 106 cells as
previously described [37-39].
In some instances, as indicated, the number of FL-
treated splenocytes given was adjusted so that an equiva-
lent number of T cells (defined as T-cell receptor
[TCR]αβ+ CD4+ or CD8+ cells) was infused. For LN T-cell
infusion, T cells were enriched by passing cells through a
goat anti-mouse and goat anti-rat Ig–coated column
(Biotex, Edmonton, Canada). To obtain a more highly
purified T-cell population, LN T cells were isolated by
positive selection using anti-TCRα/β-fluorescein isothio-
cyanate (FITC) and anti-FITC microbeads and a magnetic
separation system. Anti-TCRα/β-FITC (PharMingen, San
Diego, CA) was added at a concentration of 0.2 µL/106
cells, incubated at 4°C for 15 minutes, and washed 2 times.
Anti-FITC MicroBeads (Miltenyi Biotec, Auburn, CA)
were then added to cells at a concentration of 10 µL/107
cells for 15 minutes, washed, and then run over a type VS
+ MACS column in a SuperMACS magnet (Miltenyi
Biotec). Positively selected cells were eluted from the col-
umn, washed, and placed in another MACS column. The
purity of T cells was ≥98%.
Flow Cytometric Analysis
Splenocytes from control or FL-treated B6 donors (3 per
group) were assessed for the following antigens: Thy1.2,
TCRα/β, TCRγ/δ, CD3ε, CD4, CD8α, CD11b, CD11c,
CD19, Gr-1 (PharMingen), and DEC-205 (ATCC, Manas-
sas, VA). For DLI, the donor or host source of T cells,
B cells, and monocyte/granulocyte lineages was assessed
using murine antibodies (mAbs) from the above panel along
with mAbs directed toward CD45.1 and CD45.2 (PharMin-
gen). All studies were performed with 2- or 3-color flow
cytometry using ﬂuorescein-, phycoerythrin-, or biotin-con-
jugated mAbs. Results were obtained using a FACScalibur
(Becton Dickinson, San Jose, CA). Forward-scatter and side-
scatter settings were gated to exclude debris. A total of
10,000 cells were analyzed for each determination.
Graft-Versus-Host Disease
Recipients were monitored for signs of GVHD,
including ruffled fur, diarrhea, hunched posture, and
lethargy, and were weighed 2 times per week [40]. Liver,
lung, colon, skin, spleen, and thymus samples were
obtained for histological assessment using a semiquantita-
tive published scoring system (grades 0.5 to 4.0) [40]. All
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samples were coded and reviewed by a single individual
(A.P.-M.) who was unaware of the outcome of the
experiments.
Thoracic Duct Cannulation
A cannula was inserted into the thoracic duct of each
recipient at the time of peak cell proliferation post-BMT,
which was 6 days after splenocyte infusion. Cells were then
collected for 18 hours [38,39].
Immunohistochemistry
Immunoperoxidase staining of fixed cryostat sections
was performed using biotinylated mAbs, avidin-biotin
blocking reagents, ABC-peroxidase conjugate and DAB
chromogenic substrate as described [41]. The biotinylated
mAbs used were as follows: anti-CD4 (GK1.5), anti-CD8
(2.43), anti-Mac-1 (M1/70), anti-Gr-1 (RB6-8C5), anti-I-Ak
(11-5.2), anti-I-Ab (KH74), anti-B7.1 (1G10), and anti-B7.2
(GL1) (PharMingen). Representative sections from each tis-
sue block were stained with hematoxylin and eosin for
histopathologic assessment.
Mixed Lymphocyte Reaction
For quantifying mixed lymphocte reaction (MLR)
responses, LN T cells from B6 mice were mixed with irradi-
ated (30 Gy) T cell–depleted splenocyte stimulators from
B10.BR mice [39]. Because FL increases the proportion of
DCs that express high levels of MHC class II antigens, and
because the T-cell constituency of the spleen is affected by
FL protein treatment, we elected to analyze the MLR
responses of puriﬁed CD4+ T cells from nontreated or FL
protein–treated mice. Cells were suspended in MLR
medium consisting of Dulbecco’s minimal essential medium,
10% fetal calf serum, 2-mercaptoethanol (5 × 10–5 mol/L),
10 mmol/L HEPES buffer, 1 mmol/L sodium pyruvate,
amino acid supplements, and antibiotics. Cell responders
(105) and irradiated stimulators (105) were plated in repli-
cates of 6 into 96-well round-bottom plates and placed at
37°C with 10% CO2 for 2 to 6 days. Microtiter wells were
pulsed with tritiated thymidine (1 µCi) for 18 hours before
harvesting, and cells were counted in the absence of scintil-
lation ﬂuid on a β plate reader. Changes in cells counts were
calculated by subtracting the syngeneic proliferative
response from the allogeneic proliferative response.
Bulk cultures were established with 0.5 × 106 responders
and 0.5 × 106 irradiated stimulators per mL and cultured
under the same conditions used for microtiter wells, and
supernatant was collected from bulk cultures for cytokine
enzyme-linked immunosorbent assay (ELISA) analysis
(R & D Systems, Minneapolis, MN). Sensitivity of the
assays was 1.5 to 4.0 pg/mL for each assay. A standard curve
using recombinant protein was generated with each assay.
Statistical Analyses
Groupwise comparisons of continuous data were made
by Student t test. Survival data were analyzed by lifetable
methods using the Mantel-Peto-Cox summary of chi square.
RESULTS
In Vivo FL Treatment of Donors Does Not Alter the
T Cell–Mediated Capacity of Allogeneic Splenocytes
to Induce Lethal GVHD
To determine whether donor pretreatment with FL
would alter the capacity of allogeneic T cells to induce
GVHD, B6 donor mice were treated with FL for the 10 days
just prior to spleen harvesting. Spleen cells from FL-treated
or nontreated controls (15 × 106 cells/recipient) were com-
bined with B6 T cell–depleted BM from nontreated controls
and infused into irradiated B10.BR recipients. Data from
2 replicate experiments indicated that recipients of FL-
treated cells had a signiﬁcantly higher survival rate than did
recipients of control spleen cells (56% and 0%, respectively;
P < .0001) (Figure 1). Weight curves paralleled survival
curves (data not shown). These data indicate that GVHD
lethality is reduced when splenocytes from FL-treated
donors are infused into lethally irradiated recipients.
The number of splenocytes obtained from FL-treated
donors was significantly greater (P = .0055) than that
obtained from nontreated controls (271 ± 58 × 106 and
84 ± 10 × 106, respectively) (n = 5 experiments). Flow
cytometry of donor B6 splenocytes indicated that FL
resulted in higher proportions of myeloid-related DCs
(CD11c+CD8α–; 24% versus 2%) and lymphoid-related
DCs (CD11c+CD8α+; 25% versus 1%; CD11c+DEC-205+;
21% versus 4%; CD11c+ CD11bdull/–; 32% versus 3%) and
lower proportions of T cells as deﬁned by the expression of
TCRα/β + or CD3ε+ and CD4+ (9% versus 19%) or CD8+
antigens (5% versus 11%). The proportion of FL-treated
spleen composed of CD19+ B cells and TCRγδ cells was also
decreased (26% versus 58% and 0.6% versus 0.9%, respec-
tively). However, the proportion of NK1.1 cells (2.4% ver-
Figure 1. A Kaplan-Meier plot shows that recipients of Flt3 ligand
(FL)-treated splenocytes had a signiﬁcantly (P < .0001) higher survival
rate than did recipients given control splenocytes. Splenocytes obtained
from FL-treated donors have a reduced graft-versus-host disease lethal-
ity capacity compared with that of control splenocytes infused at equiva-
lent cell doses into lethally irradiated recipients. B6 donors were treated
with FL (10 µg/day × 10 days). Heavily irradiated B10.BR recipients
were reconstituted with bone marrow (BM) from control donors.
Cohorts received no splenocytes or splenocytes (15 × 106 cells/mouse)
from either control or FL-treated donors, as indicated. Data from
2 replicate experiments are shown.
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sus 2.5%) was not changed by FL, resulting in an overall
increase in NK-cell number of about 3- to 4-fold due to the
increase in splenocyte number induced by FL administra-
tion. The administration of 15 × 106 splenocytes from FL-
treated donors provided about 50% of the total number of
CD4+ and CD8+ T cells as from nontreated control donors.
The higher survival rate in recipients of FL-treated
donor splenocytes could be due to the infusion of fewer
T cells. Alternatively or in addition, the reduced GVHD-
induced mortality could be due to either impaired T-cell
function or the regulatory effect of non–T-cell accessory
cells present in the splenocyte inoculum, which inhibited
GVHD generation. Although the number of splenocytes
from FL-treated donors was about 3-fold higher than that of
the nontreated controls, the absolute number of splenic
TCRαβ+ cells was only slightly higher in FL-treated donors
(36 ± 4 × 106 versus 28 ± 3 × 106; P = .07). Compared with
that from the controls, the spleen obtained from FL-treated
donors had no signiﬁcant differences in TCRαβ+ CD4+ cells
(15 ± 1 × 106 versus 17 ± 1 × 106; P = .10) and modestly
higher numbers of TCRαβ+ CD8+ (11 ± 1 × 106 versus 16 ± 1
× 106; P = .03).
To determine whether the lower GVHD-induced mor-
tality was related to the absolute number of donor T cells
infused, studies were performed in which the number of
donor splenocytes infused was adjusted so that recipients
were given the same number of donor TCRαβ+ T cells. Data
from 4 pooled experiments (32 mice per group) indicate that
the actuarial survival rate of recipients receiving an equal
number of TCRαβ+ T cells from FL-treated compared with
the survival rate of nontreated controls was similar (13% and
0%, respectively; P = .41) (data not shown). Weight curves
were also similar in the 2 groups of mice (data not shown).
In a separate study, we analyzed expansion of donor
T cells in B10.BR recipients given T cells from FL-treated
or control B6 donors. The splenocyte number in the FL-
treated group was adjusted so these recipients received the
same number of donor CD4+ T cells (4 × 106) and CD8+ T cells
(3.3 × 106) as did the control recipients that were given 25 ×
106 splenocytes (total, 7.3 × 106 T cells). Thoracic duct lym-
phocytes were assessed on day 6 post-BMT, and donor
T cells were noted to have expanded in both groups, with
7.4-fold (controls) and 5.3-fold (FL-treated) more T cells
retrievable compared with the number of cells that had been
infused (5 mice per group were analyzed). The majority of
T cells were TCRαβ+ CD8+ (12.5-fold and 10-fold expan-
sions over the number of cells infused for control versus FL-
treated recipients, respectively) and a minority were TCRαβ+
CD4+ (3.2-fold and 1.4-fold expansions over the number of
cells infused for control and FL-treated recipients, respec-
tively) in both groups. Thus, FL treatment of donors did not
appear to substantially alter the expansion of donor T cells
infused into lethally irradiated recipients on day 0 of BMT.
To infuse equivalent numbers of TCRα/β cells from FL-
treated and control donors, a higher total number of non-
T cells from FL-treated donors was infused in vivo. Because
activated NK as well as NK/T cells may affect GVHD gen-
eration, we repeated the above experimental design using
NK1.1-depleted splenocyte populations. As above, an identi-
cal absolute number of TCRαβ+ T cells were infused from
FL-treated or control donors. Recipients (8 per group)
receiving spleen cells from FL-treated or control donors had
similar actuarial survival rates (P > .35), regardless of whether
NK cells were depleted prior to infusion (survival = 0% in all
groups; median survival times [MST] ranged from 27 to
29 days) (data not shown). Thus, the potential activation of
NK cells or NK/T cells by FL did not appear to inﬂuence
the kinetics or incidence of GVHD-induced lethality.
To directly assess the potential effects of FL on donor
T-cell function and to exclude the effects of other non–T cell
populations present, studies were performed using puriﬁed
T cells from FL-treated donors or nontreated controls. The
in vitro MLR proliferation of highly puriﬁed T cells from
FL-treated or nontreated controls yielded similar maximum
proliferation, although the kinetics of proliferation responses
were shifted by 1 day in cultures of FL-treated T cells com-
pared with that of control T cells (day 4 and day 3, respec-
tively) (Figure 2). The peak response at day 3 is typical for
this strain combination analyzed under these MLR condi-
tions. Supernatants were obtained from MLR cultures on
days 2, 4, and 6 of culture. Interleukin (IL)-2 and interferon
(IFN)-γ concentrations paralleled the kinetics of prolifera-
tion with peak IL-2 detected on day 2 in control cultures and
day 4 in cultures established using T cells from FL-treated
donors (peak values, 109 to 111 pg/mL for both cultures).
IFN-γ levels peaked in controls on day 4 (1197 pg/mL) and
on day 6 in cultures containing T cells from FL-treated
donors (962 pg/mL). Neither IL-4 nor IL-10 T helper (Th)2
cytokines were detectable or present in low concentrations
(<15 pg/mL) in both cultures at all time points. Cultures
established from FL-treated and control donors had simi-
lar concentrations of IL-13 protein detected on day 4
(28 pg/mL and 29 pg/mL, respectively) and day 6 (74 pg/mL
and 111 pg/mL, respectively) of culture. Thus, T cells from
Figure 2. Puriﬁed T cells from Flt3 ligand (FL)-treated donors have
similar kinetics and comparable peak responses to host alloantigen-
bearing stimulators as assessed by in an in vitro mixed lymphocyte reac-
tion assay. Highly purified (>98% pure) T-cell receptor αβ+ T cells
were isolated from FL-treated or control B6 donors and placed with
T cell–depleted, irradiated B10.BR splenic stimulator cells. On the
indicated days of culture, wells were pulsed with tritiated thymidine
and analyzed for the degree of proliferation as denoted by cpm. T cells
from FL-treated donors peaked 1 day later than controls, although the
peak responses were comparable in the 2 groups.
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FL-treated donors appeared to have similar proliferation
responses to allogeneic stimulator cells and produced a simi-
lar pattern of Th1 and Th2 cytokines, albeit proliferation
and cytokine production was somewhat delayed in the time
to peak response compared with controls.
To determine the in vivo GVHD response capacity of
purified T cells from FL-treated and nontreated control
donors, lethally irradiated allogeneic B10.BR recipients
were given 3 × 106 puriﬁed B6 T cells from FL-treated or
control donors. Pooled data from replicate experiments
demonstrated that T cells from FL-treated donors had a
similar capacity to cause lethal GVHD as did nontreated
controls, with long-term (98-day) survival rates of 44% and
27%, respectively (P = .39) (Figure 3). Weight curves were
similar in the 2 groups (data not shown). Collectively, these
data indicate that FL treatment of donors causes a 3-fold
increase in the absolute numbers of cells that can be
obtained without substantially increasing the total number
of T cells, the in vitro alloresponses of these T cells, or their
in vivo GVHD lethality capacity.
FL Treatment of Lethally Irradiated Recipients 
of Allogeneic Donor Splenocytes Increases 
GVHD-Induced Mortality
Our data indicate that FL treatment does not affect the
GVHD capacity of donor splenocytes, suggesting that FL
treatment may be safely used as a mobilizing agent for
collecting hematopoietic cells to reconstitute allogeneic
recipients. FL administration has been shown to facilitate
antitumor immune responses and to support lymphohe-
matopoiesis. Because of these properties, FL treatment of
the recipient post-BMT represents a potential modality for
facilitating immune and lymphohematopoietic recovery. To
determine whether FL treatment of the recipient early post-
BMT would affect GVHD-induced lethality, lethally irradi-
ated B10.BR recipients of B6 allogeneic donor splenocytes
(15 × 106 cells/recipient) were given saline or FL injections
from days 0 to 20 post-BMT. Data from 3 replicate experi-
ments indicate that recipients treated with FL had a signiﬁ-
cantly lower actuarial survival rate compared with that of the
saline-injected controls (4% versus 22%, respectively; P =
.0057) (Figure 4). Moreover, the MST of recipients of FL
was significantly shorter than controls (22 days versus 37
days, respectively), indicating that GVHD lethality was
accelerated by FL treatment of the recipient.
To quantify the degree of GVHD augmentation and to
determine how FL treatment of recipients from days 0 to 20
would affect T cell–mediated GVHD lethality, experiments
were performed in which graded doses (1, 3, or 6 × 106 cells)
of highly puriﬁed B6 LN T cells were infused along with BM
into lethally irradiated B10.BR recipients (Figure 5). By using
puriﬁed LN T cells rather than splenocytes, we eliminated the
potential effect of FL on splenic non–T cell populations (eg,
DCs) that could be expanded or modiﬁed by FL. LN T cells
contained 53% CD4+ and 42% CD8+ T cells. There was a
correlation between the dose of LN T cells infused and mor-
tality rates. The mortality rate for saline-treated recipients
given 106 T cells was 0%; for those given 3 × 106 T cells, 75%;
and for those given 6 × 106 T cells, 100%. The mortality rate
for FL-treated recipients given 106 T cells was 25% (P = .074
when compared with controls); for those given 3 × 106 T cells,
100% (MST = 32 days) (P = .0051 when compared with con-
trols); and for those given 6 × 106 T cells, 100% (MST = 18
days) (P = .0026 when compared with controls). Consistent
with the LN data, a cohort of FL-treated recipients that was
Figure 3. A Kaplan-Meier plot shows no signiﬁcant difference in sur-
vival (P = .39) between recipients of T cells obtained from control
versus ﬂt3 ligand (FL)-treated donors. Puriﬁed T cells obtained from
FL-treated donors have a graft-versus-host disease (GVHD) lethality
potential comparable to that of T cells obtained from control donors.
T cells (3 × 106 cells/recipient) were combined with T cell–depleted
bone marrow (BM) obtained from nontreated B6 controls and infused
into irradiated B10.BR recipients. One cohort received no supplemen-
tal T cells and served as a no GVHD control. Data from 2 replicate
experiments were pooled.
Figure 4. A Kaplan-Meier plot shows that recipients treated with ﬂt3
ligand (FL) had a signiﬁcantly lower survival rate compared with recipients
given supplemental splenocytes and saline (P = .0057). Early post–bone
marrow transplantation (BMT) FL treatment resulted in a signiﬁcant
increase in graft-versus-host–induced lethality compared with controls.
Irradiated B10.BR recipients were reconstituted with B6 BM cells.
Cohorts received no supplemental splenocytes or supplemental spleno-
cytes (15 × 106/recipient) and either saline or FL protein (10 µg/day from
days 0-20). Data from 3 replicate experiments were pooled.
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given 15 × 106 splenocytes (containing 5 × 106 T cells: 3 × 106
CD4+ and 2 × 106 CD8+ T cells) had a signiﬁcantly lower sur-
vival rate compared with that of saline treated controls (MST
= 23 days versus 34 days, respectively) (data not shown). All
the FL-treated recipients given splenocytes died by day 25
post-BMT, compared with day 60 post-BMT for controls (P =
.0074). Because FL-treated recipients given 3 × 106 T cells had
an actuarial survival rate that was comparable to saline-treated
recipients given 6 × 106 T cells (P = .15), it is likely that FL
treatment of the recipient results in the equivalent of an
approximately 2-fold increase in GVHD-associated mortality.
To determine whether certain GVHD target organs were
more susceptible to the GVHD-augmentary effect of FL,
cohorts of FL- or saline-treated B10.BR recipients of B6 allo-
geneic BM and supplemental splenocytes were killed on days
7 or 14 post-BMT for histopathological analysis. GVHD tar-
get organs examined included colon, liver, lung, skin, spleen,
and thymus. At both times and with regard to all organs
examined, recipients of BM without supplemental splenocytes
had signiﬁcantly lower mean GVHD scores than did recipi-
ents of supplemental splenocytes (Table). In both groups,
mean GVHD scores in all organs in were comparable on day
7 post-BMT. However, by day 14 post-BMT, FL-treated
recipients were observed to have higher colon, liver, and
spleen mean GVHD scores than did saline-treated controls.
Immunohistochemistry analyses performed on 3 different
GVHD target organs (liver, skin, and lung) from control and
FL-treated recipients revealed no signiﬁcant differences in
the frequency of cells expressing MHC class I or II antigens
of either donor or host origin at either time (data not shown).
In addition, no differences were detected in the frequency of
cells expressing B7 ligands (B7-1 or B7-2). Therefore, the
increase in GVHD in FL-treated recipients did not appear to
be due to an increased frequency of host or donor APCs, as
measured by expression of MHC class II antigens or B7
ligands. However, because the day 7 and day 14 post-BMT
tissue sections were not tested with myeloid- or lymphoid-
specific DC mAbs, we cannot exclude the possibility of a
stimulating effect by FL on DC populations in the recipient.
Effect of FL on Graft-Versus-Host Disease Induced by
Delayed Lymphocyte Infusion
The release of proinflammatory cytokines temporarily
associated with the conditioning regimen can augment the
GVHD response of donor lymphocyte infusions. GVHD
lethality is lessened when donor cells are given later post-BMT
rather than on the day of BMT. To determine whether FL
treatment would increase GVHD lethality when given later
post-BMT, B6 recipients that had been reconstituted with T
cell–depleted allogeneic B10.BR BM were given FL from days
18 to 39 post-BMT and DLI on day 21 post-BMT. FL-treated
recipients given DLI had a signiﬁcantly lower survival rate at 6
months post-BMT compared with that of controls (25 × 106
cells: 40% versus 90%, P = .013; 50 × 106 cells: 20% versus
100%, P = .0002) (Φιγυρε 6). Because the survival rate of con-
trols that received DLI at 50 ¥ 106 cells was higher than that of
FL-treated recipients of 25 ¥ 106 cells (100% versus 40%, P =
.0022), FL treatment was associated with a >2-fold increase
in the rate of lethal GVHD associated with DLI.
Figure 5. A Kaplan-Meier plot shows that recipients given supple-
mental T cells at a dose of 6 × 106 cells and saline had a survival rate
comparable to ﬂt3 ligand (FL)-treated recipients given 3 × 106 T cells
(P = .15), consistent with an approximate 2-fold increase in graft-versus-
host disease (GVHD) lethality conferred by FL treatment. Early
post–bone marrow transplantation (BMT) FL treatment resulted in an
approximate 2-fold increase in GVH-induced lethality compared with
controls. Irradiated B10.BR recipients were reconstituted with B6 BM
cells. Cohorts received no supplemental T cells or supplemental T cells
at the indicated doses and either saline or FL protein (10 µg/day on
days 0-20). Eight mice per group received transplants. 
Degree of GVHD by Organ Involved on Days 7 and 14 Post-BMT in FL-Treated, Lethally Irradiated Recipients of Allogeneic Donor Grafts*
Group Day Colon Liver Lung Skin Spleen Thymus
BM only 7 0.9 (0.3)† 0.6 (0.4)† 0.3 (0.3)† 0.0 (0.0)† 1.3 (0.4)† 0.4 (0.4)†
Spleen 7 2.7 (0.2) 2.5 (0.3) 1.5 (0.0) 1.8 (0.1) 2.2 (0.2) 3.3 (0.3)
Speen/FL 7 2.9 (0.2) 2.4 (0.2) 1.3 (0.3) 1.1 (0.4) 2.1 (0.2) 3.3 (0.3)
BM only 14 1.0 (0.0)† 0.7 (0.3)† 0.5 (0.3)† 0.4 (0.2)† 0.4 (0.2)† 0.6 (0.6)†
Spleen 14 3.4 (0.2) 3.2 (0.2) 3.0 (0.3) 2.9 (0.2) 3.1 (0.2) 3.6 (0.4)
Spleen/FL 14 3.9 (0.2)† 4.0 (0.0)† 3.2 (0.4) 3.0 (0.0) 3.7 (0.3)† 3.5 (0.3)
*B10.BR recipients were lethally irradiated and given allogeneic B6 T-cell–depleted BM only or with supplemental spleen cells (25 × 106
cells/recipient) as indicated. Cohorts of mice receiving supplemental splenocytes were treated with FL from day 0 to day 20 (Spleen/FL). On days 7
and 14 post-BMT, 4 mice per group were killed for histological analysis. Values for each GVHD target organ are mean (SD). GVHD indicates
graft-versus-host disease; BMT, bone marrow transplantation; FL, ﬂt3 ligand.
†P < .05 of either BM or Spleen/FL versus Spleen group.
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To determine whether FL treatment results in the
expansion of donor T cells from the DLI source, irradiated
B10.BR recipients were reconstituted with B6 T cell–
depleted BM and then treated with FL (days 11 to 27). To
maximize the potential effect of FL treatment on DLI
expansion, DLI was given on day 21, the time of peak FL-
mediated DC expansion in vivo. A cohort of recipients that
received no DLI served as controls for assessing the effect of
DLI on donor and host populations. Splenic phenotyping
(3 mice per group) was performed on day 28 post-BMT,
1 week post-DLI administration (data not shown). Com-
pared with controls, FL-treated recipients of DLI had a
3.6-fold increase in CD4+ DLI-derived cells (P = .04) and a
1.8-fold increase (not significant, P = .15) in CD8+ DLI-
derived cells resulting in a 2.5-fold higher total number of
DLI-derived T cells in FL-treated compared with control
recipients (28 ± 12 versus 11 ± 1 × 106, respectively; P = .06).
FL-treated recipients also had significantly higher total
numbers of splenocytes and signiﬁcantly higher numbers of
donor BM–derived CD4+, CD8+, and CD11b+ cells than did
controls, an expected result considering the hematopoietic-
stimulating effects of FL. Host T-cell populations were not
signiﬁcantly affected by FL treatment. Thus, FL treatment
expanded DLI-derived T cells and donor BM–derived cells.
The expansion of DLI-derived T cells was associated with
increased DLI-associated GVH lethality.
DISCUSSION
Several major conclusions can be derived from this study.
FL administration to donors for a period of 10 days resulted
in a substantial expansion in the number of splenic DCs.
When equivalent numbers of splenocytes were injected from
control or FL-treated donors, GVHD lethality was signiﬁ-
cantly lessened. However, FL treatment did not affect the
induction of GVHD lethality when the number of spleno-
cytes administered was adjusted to provide equivalent num-
bers of TCRα/β+ T cells. Moreover, puriﬁed T cells from FL-
treated or control donors generated comparable GVHD
lethality in vivo. Therefore, FL treatment of donors increases
the available number of DCs and other non–T-cell populations
without affecting the alloresponse capacity of T cells exposed
to FL in vivo. In contrast, FL treatment of irradiated recipi-
ents of allogeneic grafts from days 0 to 20 post-BMT signiﬁ-
cantly augmented GVHD lethality. In addition, FL-treated
recipients of DLI had a signiﬁcant increase in DLI-associated
GVHD lethality, indicating that FL acceleration of GVHD
was not restricted to the presence of FL during the peri-
BMT period. Thus, post-BMT FL treatment of the heavily
irradiated allogeneic BM recipient is associated with an
increased rate of GVHD lethality response.
With PBSC infusions, larger numbers of T cells are
given than with BM grafts, yet acute GVHD incidence and
severity in matched sibling donor transplantation appear to
be no greater than in BM grafts [12,15]. An interesting
observation in our present study was that FL treatment of
donors, which is currently being studied as a mobilizing
agent for autologous transplantation, did not affect the
GVHD-inducing capacity of the donor T cells in this par-
ticular murine allogeneic BMT setting. Treatment of
donors with FL resulted in a dramatic expansion in the
number of both myeloid- and lymphoid-related DCs. In
vivo FL-generated DCs have been shown to process and
present soluble antigen when injected in vivo [42]. Once
infused into irradiated recipients, FL-generated DCs could
increase GVHD responses by the uptake of host MHC
antigens released as a consequence of conditioning or
GVHD-induced tissue injury and present these antigens to
MHC-identical donor T cells contained in the inoculum.
This process is called indirect allorecognition. However,
the infusion of FL-treated splenocytes containing higher
absolute numbers of and equivalent numbers of T cells of
both DC types caused comparable GVHD lethality. There-
fore, either these donor DCs are not critical for GVHD
generation under the conditions used in our experiments,
or there are cell populations contained in the inocula that
counterbalance the increased GVHD induction potential of
a high number of donor DCs that are infused in the spleen
inoculum. With respect to the former possibility, there is
evidence that host APCs, possibly including DCs, are
required for optimal GVHD induction in a system of minor
histocompatibility antigen disparity [43]. This pathway of
allorecognition is called the direct pathway. Although the
indirect pathway has been implicated in some settings for
solid organ graft rejection [44], there is no evidence regard-
ing the importance of this pathway in a BMT setting. Con-
sistent with the lack of an absolute requirement for donor
DCs in GVHD generation is the fact that lethal GVHD
can be generated in sublethally irradiated or noncondi-
tioned mice [39] given puriﬁed donor T cells without sup-
plementation with BM-derived cells. However, under the
proinﬂammatory conditions typically induced by pre-BMT
myeloablative conditioning regimens and donor BM rescue,
Figure 6. A Kaplan-Meier plot shows ﬂt3 ligand (FL)-treated recipi-
ents given delayed lymphocyte infusion (DLI) had a signiﬁcantly lower
survival rate than did controls (25 × 106 cells; P = .013; 50 × 106 cells;
P = .0002). FL treatment of recipients increases DLI-associated graft-
versus-host lethality. Irradiated B10.BR recipients were reconstituted
with B6 T-cell–depleted bone marrow (BM) and given no supplemen-
tal splenocytes (not shown) or DLI (25 or 50 × 106 splenocytes) from
B6 donors. Cohorts of recipients as indicated were treated with FL
from days 18-39 post–bone marrow transplantation (BMT). Ten mice
per group received transplants.
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the indirect allorecognition pathway could play a role in
GVHD induction. In the present experiments, recipients
were lethally irradiated, rescued with donor BM cells, and
given FL. Thus, the best opportunity for the contribution
of the indirect allorecognition pathway may exist under
these circumstances.
With respect to cells that may downregulate GVHD
lethality and counterbalance only donor DC effects, there
are several cell populations that may have suppressed the
GVHD process that occurred with a high number of donor
DCs. For example, activated NK cells [45] and NK cells
coexpressing T-cell determinants (NK/T cells) [46] have
been shown to inhibit GVHD responses when present in
the early post-BMT period. NK cells produce TGFβ and
NK/T cells produce IL-4. In some systems, these cytokines
have been associated with decreased GVHD lethality medi-
ated by donor T cells [46,47]. However, depletion of NK
and NK/T cells from the donor inocula did not alter the
GVHD potential of FL-treated splenocytes compared with
control splenocytes. The DCs expanded by FL include
both myeloid- and lymphoid-related DCs. In vivo FL-gen-
erated myeloid DC subsets have been shown to produce
large amounts of Th2 cytokines (IL-4 and IL-10) along
with the Th1 cytokines (IL-2 and IFN-γ), but the lym-
phoid-related DCs were shown to produce high levels of
Th1 but little or no Th2 cytokine [42]. In this strain com-
bination, our previous results have indicated that IFN-γ and
a low amount of IL-10 inhibit GVHD lethality, but IL-4 or
high levels of IL-10 accelerate GVHD lethality [48,49]. It
was possible that the donor T cells exposed to FL in vivo
could have acquired a Th2 phenotype [42,50], as has been
demonstrated in G-CSF–mobilized PBSC in humans [51-
53] and with splenocytes from G-CSF–treated mice
[54,55]. However, FL pretreatment resulted in a delay of
only 1 day in the time to peak alloresponses in vitro, which
was associated with a delay of 2 days in the production of
IFN-γ levels. No Th2 cytokines were detectable in
alloMLR cultures established using highly puriﬁed T cells
obtained from control or FL-treated donors. Moreover,
GVHD lethality was not signiﬁcantly different in recipients
of purified T cells compared with control or FL-treated
donors. In aggregate, these data indicate that FL treatment
that markedly expands DCs does not affect the GVHD
lethality potential of splenocytes containing equivalent
numbers of TCRα/β+ T cells or highly puriﬁed T-cell pop-
ulations. Because FL is an effective mobilizing agent for
PBSC and because the GVHD risk is not increased by
donor FL treatment, FL could be especially advantageous
for this purpose if the infusion of donor DCs in the PBSC
graft would provide an antitumor effect in BMT recipients.
In addition, FL has been shown to exhibit synergy with GM-
CSF and G-CSF [11]. Additional studies are indicated to
determine whether FL and either GM-CSF and G-CSF
would facilitate lymphohematopoiesis and augment a graft-
versus-leukemia effect without increasing GVHD risk
when given to donors for infusion on the day of BMT or as
DLI later post-BMT.
In allogeneic BMT recipients, FL treatment beginning
on the day of BMT accelerated GVHD induction. The typi-
cal GVHD target organs in the controls were the colon, liver,
and skin, and the disease was modestly more severe in the
FL-treated recipients analyzed on day 14 post-BMT. FL
treatment initiated on the day of BMT did not substantially
alter the frequency of cells expressing host or donor MHC
antigens or B7 ligands, any of which could have driven donor
antihost T-cell responses via either direct or indirect
allorecognition pathways. Our studies with DLI indicate that
FL treatment resulted in a greater expansion of DLI-derived
T cells, especially CD4+ T cells. Therefore, one explanation
for our ﬁnding that FL treatment of the recipient accelerates
GVHD-induced lethality is that FL treatment of the recipi-
ent results in greater numbers of donor T cells. Because FL
treatment did not appear to augment the expression of several
critical cell surface antigens surveyed in various GVHD tar-
get tissues, we have begun to search for soluble factors that
may be secreted in higher amounts in FL-treated recipients.
Preliminary studies have focused on the induction of proin-
ﬂammatory responses early in the post-BMT period. Data
from an RNase protection assay (RPA) using day 7 post-BMT
splenocytes obtained from FL or control recipients (4 per
group) have shown a 12.5-fold increase in tumor necrosis fac-
tor (TNF)-α, an 8.5-fold increase in both IL-12p35 and IL-
12p40, a 8-fold increase in IL-1α and a 5.4-fold increase in
IL-1β messenger (m)RNA when normalized to mRNA for a
housekeeping gene (data not shown). At this time, serum was
collected and sufﬁcient material was available for one assay.
Because TNF-α mRNA showed the greatest fold increase,
serum TNF-α concentrations were determined by ELISA.
FL treatment resulted in signiﬁcantly higher levels of TNF-α
than saline treatment (95 ± 5 versus 58 ± 10 pg/mL, respec-
tively; P = .006). In contrast, FL treatment of non-BMT con-
trols revealed no detectable TNF-α in the circulation (not
shown). Taken together, our preliminary data indicate that FL
given to lethally irradiated allogeneic recipients is associated
with higher amounts of TNF-α mRNA and higher circulat-
ing amounts of TNF-α protein. In addition, RPA data indi-
cate that the mRNA for several pro-inﬂammatory cytokines is
higher as assessed day 7 post-BMT on splenocytes of FL-
treated compared with control recipients. Although we do
not know the cellular source of these proinflammatory
cytokines, likely candidates are cells of the monocyte/macro-
phage/DC or NK lineages that have been activated by FL
treatment, conditioning, GVHD, or release of endotoxin into
the circulation.
TNF-α, IL-12, and IL-1 have all been implicated in
GVHD generation [56,57]. Depending on the model sys-
tem, neutralization of TNF-α has been shown to reduce
GVHD target organ injury, and to be associated with pro-
longed survival [56,57]. The infusion of donor T cells that
lack the p55 TNF receptor results in less GVHD than the
infusion of wild-type T cells, suggesting that TNF-α pro-
duction drives donor T-cell activation and/or expansion
[58]. IL-12 is known to be a key regulator of alloreactivity in
acute GVHD responses, as has been shown by several inves-
tigators [59-62]. IL-12 can have both positive and negative
effects on GVHD generation. For example, a single high
dose of exogenous IL-12 given on the day of BMT inhibits
GVHD by upregulating Fas on donor T cells and by upreg-
ulating IFN-γ production early post-BMT [59,63,64]. We
[48] and others [63] have shown that IFN-γ production by
donor T cells suppresses GVHD lethality. In contrast, pro-
longed neutralization of endogenous IL-12 is effective in
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inhibiting acute GVH responses [61,62]. Thus, high levels
of IL-12 present on day 7 post-BMT could have a detri-
mental effect on survival in recipients given allogeneic
splenocytes. Finally, the neutralization of IL-1 has been
shown in some systems to reduce GVHD lethality [58].
Future studies will be required to determine whether TNF-α,
IL-12, or IL-1 alone or in combination or other as yet
untested cytokines were critical to the accelerated GVHD
processes observed with FL administration.
Regardless of the mechanism(s) involved in FL-accelerated
GVHD induction, our studies interject a note of caution for
human trials that would incorporate the early post-BMT
administration of FL to promote lymphohematopoietic
recovery or the later post-BMT use of FL with DLI to
induce antitumor responses. However, there is no current
cause for hesitation in the use of FL treatment of allogeneic
donors based on the outcome of the assessment of GVHD
induction in our murine studies. Such donor treatment
alone or in combination with GM-CSF or G-CSF may rep-
resent a means of achieving rapid lymphohematopoietic
reconstitution without GVHD and potentially with the
preservation of graft-versus-leukemia responses.
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